Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.

Bibiana Quirant-SanchezJosé V Hervás-GarcíaAina Teniente-SerraLuis BrievaEster Moral-TorresAntonio CanoElvira MunteisMaría J MansillaSilvia Presas-RodriguezJuan Navarro-BarriusoCristina Ramo-TelloEva M Martínez-Cáceres

Published in: CNS neuroscience & therapeutics (2018)

The results support that immune-monitoring of lymphocyte subpopulations in peripheral blood is a promising tool to select RRMS candidate for fingolimod treatment.

Keyphrases

multiple sclerosis
peripheral blood
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
white matter
peritoneal dialysis
patient reported outcomes